Previous close | 3.9400 |
Open | 5.5600 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 110.00 |
Expiry date | 2024-04-26 |
Day's range | 3.9400 - 5.5600 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Key Insights Moderna to hold its Annual General Meeting on 6th of May CEO Stephane Bancel's total compensation includes...
When it comes to cancer, there’s innovation both on the diagnostics and the treatment front thanks to messenger RNA, or mRNA, a genetic material we all got acquainted with during the COVID-19 era as it allowed pharmaceutical companies like Pfizer Inc (NYSE: PFE) and Moderna Inc (NASDAQ: MRNA) to develop their groundbreaking vaccines in record time. By the looks of it, this was only the beginning of the healthcare revolution that mRNA triggered. Mainz Biomed N.V. (NASDAQ: MYNZ) to revolutionize c
Investors' focus will likely be on updates on Moderna's (MRNA) expected RSV vaccine launch and its late-stage pipeline candidates when it reports first-quarter earnings.